Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
1.280
-0.110 (-7.91%)
At close: Mar 11, 2026, 4:00 PM EDT
1.240
-0.040 (-3.13%)
After-hours: Mar 11, 2026, 7:54 PM EDT
Celularity Employees
Celularity had 123 employees as of December 31, 2024. The number of employees increased by 3 or 2.50% compared to the previous year.
Employees
123
Change (1Y)
3
Growth (1Y)
2.50%
Revenue / Employee
$329,902
Profits / Employee
-$655,667
Market Cap
36.91M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 123 | 3 | 2.50% |
| Dec 31, 2023 | 120 | -105 | -46.67% |
| Dec 31, 2022 | 225 | 0 | - |
| Dec 31, 2021 | 225 | 63 | 38.89% |
| Dec 31, 2020 | 162 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 64 |
| Palatin Technologies | 29 |
| Jasper Therapeutics | 27 |
| Actinium Pharmaceuticals | 25 |
| PDS Biotechnology | 24 |
| Veru Inc. | 20 |
| Outlook Therapeutics | 17 |
| Atossa Therapeutics | 15 |
CELU News
- 1 day ago - EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga
- 1 day ago - Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - GlobeNewsWire
- 4 weeks ago - Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses - GlobeNewsWire
- 2 months ago - Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations - GlobeNewsWire
- 2 months ago - Celularity Announces Closing of Financing Transactions - GlobeNewsWire
- 2 months ago - Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision - GlobeNewsWire
- 4 months ago - Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care - GlobeNewsWire
- 5 months ago - Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - GlobeNewsWire